Mammary Cell News Volume 6.39 | Oct 9 2014

Distinct Luminal Type Mammary Carcinomas Arise from Orthotopic Trp53 Null Mammary Transplantation of Juvenile Versus Adult Mice
Scientists investigated the effect of host age on the distribution of tumor subtypes in mouse mammary chimera consisting of wild-type hosts and Trp53 nullizygous epithelium, which undergoes a high rate of neoplastic transformation. [Cancer Res] Abstract

NGF and ProNGF Simultaneously Promote Symmetric Self-Renewal, Quiescence and EMT to Enlarge the Breast Cancer Stem Cell Compartment
Researchers investigated the effects of nerve growth factor (NGF) and proNGF on the breast cancer stem cell (CSC) compartment and found that NGF or proNGF enrich for CSCs in several breast cancer cell lines. [Stem Cells] Abstract

Bioenergetic Differences between MCF-7 and T47D Breast Cancer Cells and Their Regulation by Estradiol and Tamoxifen
Researchers determined how estradiol and 4-hydroxytamoxifen affect cellular bioenergetic function in MCF-7 and T47D Estrogen receptor α⁺ breast cancer cells in serum-replete versus dextran-coated charcoal-stripped fetal bovine serum-containing medium. [Biochem J] Abstract

Generation of MCF-7 Cells with Aggressive Metastatic Potential In Vitro and In Vivo
Scientists generated “aggressive” MCF-7 breast cancer cells, which show significantly increased invasion in contrast to wild type MCF-7 cells. In addition, they analyzed whether these cell lines differ in their metastatic behavior in vivo and in expression of invasion and/or epithelial-mesenchymal transition-relevant genes. [Breast Cancer Res Treat] Abstract

Protein Kinase D1 Regulates ERα-Positive Breast Cancer Cell Growth Response to 17β-Estradiol and Contributes to Poor Prognosis in Patients
Scientists highlight the role of the serine/threonine-protein kinase D1 (PKD1) in estrogen receptor α (ERα)-positive breast cancers. Growth of ERα-positive MCF-7 and MDA-MB-415 human breast cancer cells was assayed in adherent or anchorage-independent conditions in cells overexpressing or depleted for PKD1. [J Cell Mol Med] Abstract

Flavokawain A Induces Apoptosis in MCF-7 and MDA-MB231 and Inhibits the Metastatic Process In Vitro
Researchers investigated the effects of flavokawain A (FKA) on the apoptotic and metastatic process in two breast cancer cell lines. FKA induces apoptosis in both MCF-7 and MDA-MB231 in a dose dependent manner through the intrinsic mitochondrial pathway. [PLoS One] Full Article

MicroRNA-874 Inhibits Cell Proliferation and Induces Apoptosis in Human Breast Cancer by Targeting CDK9
Scientists found that the expression level of miR-874 is down-regulated in breast cancer in comparison with the adjacent normal tissues. The overexpression of miR-874 is able to inhibit cell proliferation and induce cell apoptosis and cell cycle arrest in MCF7 and MDA-MB-231 cells. [FEBS Lett] Abstract

ERbeta1: Characterization, Prognosis, and Evaluation of Treatment Strategies in ERalpha-Positive and -Negative Breast Cancer
To investigate the utility of therapeutically targeting ERbeta1, researchers generated multiple ERbeta1 expressing cell model systems and determined their proliferative responses following anti-estrogenic or ERbeta-specific agonist exposure. [BMC Cancer] Abstract | Full Article

Up-Regulation of S100A16 Expression Promotes Epithelial-Mesenchymal Transition via Notch1 Pathway in Breast Cancer
Researchers observed that S100A16 was expressed in higher levels in human breast cancer tissues compared with paired adjacent non-cancerous tissues. Further examination showed that overexpression of S100A16 in MCF-7 cells could increase cell proliferation and colony formation. [J Biomed Sci] Abstract | Full Article

Isoflavones Extracted from Chickpea Cicer arietinum L. Sprouts Induce Mitochondria-Dependent Apoptosis in Human Breast Cancer Cells
Scientists systematically investigated the effects of isoflavones extracted from chickpea sprouts (ICS) on the human breast cancer cell lines SKBr3 and MCF-7. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays showed that ICS significantly inhibited the proliferation of both cell lines in a time-dependent and dose-dependent fashion. [Phytother Res] Abstract

CLINICAL RESEARCH

Bevacizumab and Taxanes in the First-Line Treatment of Metastatic Breast Cancer: Overall Survival and Subgroup Analyses of the ATHENA Study in France
The international Phase IIIb study, ATHENA assessed the combination of bevacizumab/taxane-based chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer in a real-life setting. Among the 365 patients included in France, median overall survival is 28.4 months, with a median time from treatment start to end of study of 36.5 months. [Bull Cancer] Abstract

All-Oral Combination of Lapatinib and Capecitabine in Patients with Brain Metastases from HER2-Positive Breast Cancer – A Phase II Study
The authors investigated efficacy and tolerability of the combination of lapatinib and capecitabine in HER2+ve BC patients with brain metastases. [J Egypt Natl Canc Inst] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

bioTheranostics Appoints Nicolas Barthelemy as President and CEO
bioTheranostics, Inc. has appointed life sciences industry veteran Nicolas Barthelemy to the position of president and CEO. [bioTheranostics, Inc. (Business Wire)] Press Release

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

Postdoctoral Position – Breast Cancer Biology (UT Southwestern)

Postdoctoral Research Fellow – Cell Cycle Regulatory Pathways in Breast Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Breast Cancer Research (The University of Texas MD Anderson Cancer Center)

Postdoctoral Position – Breast Cancer Research (Weizmann Institute of Science)

Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine)

PhD Position – Breast Cancer Research (University of Iceland Biomedical Center)

Postdoctoral Positions – Cell Death of Normal Tissue Stem Cells (Sloan-Kettering Institute)

Postdoctoral Fellow – Breast Cancer Translational Research (University of Houston – College of Pharmacy)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.